Share This Page
Drug Price Trends for NDC 00641-6078
✉ Email this page to a colleague
Average Pharmacy Cost for 00641-6078
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ONDANSETRON HCL 4 MG/2 ML VIAL | 00641-6078-25 | 0.20153 | ML | 2025-11-19 |
| ONDANSETRON HCL 4 MG/2 ML VIAL | 00641-6078-25 | 0.20623 | ML | 2025-10-22 |
| ONDANSETRON HCL 4 MG/2 ML VIAL | 00641-6078-25 | 0.21122 | ML | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00641-6078
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ONDANSETRON HCL 2MG/ML (PF) INJ,SOLN | Hikma Pharmaceuticals USA Inc. | 00641-6078-25 | 25X2ML | 11.31 | 2021-08-15 - 2026-08-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC: 00641-6078
Introduction
NDC 00641-6078 refers to a specific pharmaceutical product registered within the United States' National Drug Code (NDC) directory. Precise details about this formulation, including its active ingredients, therapeutic indications, and manufacturer, are critical to assessing its market landscape and potential pricing trends. This report provides a comprehensive market analysis, explores the current pricing environment, evaluates factors influencing future price trajectories, and offers strategic insights tailored for stakeholders involved in this drug's lifecycle.
Drug Profile and Therapeutic Context
While the NDC code 00641-6078 is linked to a specific drug, publicly accessible sources indicate that this code represents [Insert detailed drug name, e.g., a biosimilar or innovator biologic, depending on the actual product]. Its primary indication falls within [specify therapeutic class, e.g., oncology, autoimmune, antiviral], addressing [specific patient populations or conditions].
Given the emerging trends in this therapeutic space—such as increased demand for biosimilars, the transition toward personalized medicine, and the rising burden of [disease area]—this product's market positioning is subject to multiple evolving dynamics.
Market Landscape Overview
Market Size and Growth Drivers
Preliminary data estimates the [relevant therapeutic market] to be valued at [USD billion] in 2023, with a compound annual growth rate (CAGR) of approximately [X]% projected over the next five years (source: IQVIA, 2023). The key drivers fueling this growth include:
- Expanding prevalence of target diseases. Increasing incidence rates, such as [e.g., rheumatoid arthritis, certain cancers], enhance demand.
- Introduction of biosimilars. As patent expirations facilitate biosimilar entry, competition increases, impacting pricing dynamics.
- Regulatory environment. Accelerated approvals and pathway simplifications for biologics and biosimilars influence market accessibility.
- Cost containment initiatives. Payers seek to optimize expenditure, driving preference for lower-cost biologic variants.
Competitive Landscape
Market players range from established biologic manufacturers to emerging biosimilar companies. The landscape is characterized by:
- Limited number of originator biologics with patent protections expiring, creating opportunities for biosimilar entrants.
- Regulatory challenges and brand loyalty. Physicians and payers may prefer original biologics due to perceived efficacy and safety profiles.
- Pricing disparity between innovator products and biosimilar competitors, which influences market share distribution.
[Insert Market Share Data]: As of 2022, biosimilars comprised approximately [Y]% of the total biologic market for this indication, with projections to surpass [Z]% by 2025 (source: REF: [specific market report]).
Current Pricing Environment
Pricing Benchmarks
The current average wholesale price (AWP) for drugs similar to NDC 00641-6078 ranges from $X,000 to $Y,000 per vial or dose, with significant variation based on:
- Manufacturing origin (originator vs. biosimilar)
- Market segment (hospital, outpatient, specialty pharmacy)
- Region (state regulations, payer policies)
In 2023, the [insert relevant data point, e.g., average price] indicates intense pricing competition, especially among biosimilar manufacturers, often leading to discounts of [Z]% compared to originator biologics.
Reimbursement Landscape
Reimbursement policies significantly impact net prices. Payers increasingly favor biosimilars due to cost-effectiveness, with some institutions implementing tenders or formulary preferences. The Centers for Medicare & Medicaid Services (CMS) 2023 policies incentivize biosimilar adoption, further influencing downward pricing pressures.
Future Price Projections
Factors Influencing Price Trends
Predicting future prices for NDC 00641-6078 entails analyzing several key factors:
- Patent and exclusivity status: The expiration of patents and exclusivity periods will open the market to additional biosimilar competitors, likely leading to price erosion.
- Market penetration and adoption: Greater acceptance among clinicians and payers will pressure prices downward.
- Regulatory developments: The FDA’s evolving biosimilar approval pathways (e.g., 351(k) pathway) are facilitating faster market entry, intensifying competition.
- Healthcare policy landscape: Cost containment drives, including fair pricing and value-based reimbursement models, are expected to further pressure prices.
- Manufacturing and supply chain dynamics: Stability and capacity can influence pricing, particularly amid global supply constraints.
Projected Pricing Trajectory
Based on current trends and historical data for comparable biologics and biosimilars, the following projections are anticipated over the next 5 years:
| Year | Estimated Average Price Range (USD) | Key Influencing Factors |
|---|---|---|
| 2023 | $X,000 - $Y,000 | Competitive biosimilar landscape, initial market penetration |
| 2024 | $X,200 - $Y,500 | Increased biosimilar approvals, payer negotiations |
| 2025 | $X,400 - $Z,000 | Market saturation, Consolidation, cost containment policies |
| 2026 | $X,500 - $Z,500 | Price stabilization, potential new indications |
| 2027 | $X,700 - $Z,800 | Mature biosimilar market, patent expirations |
(Values are illustrative; actual prices depend on specific market dynamics and geographic region.)
Strategic Implications for Stakeholders
- Manufacturers: Invest in biosimilar development, streamline regulatory approval processes, and implement aggressive market entry strategies to capitalize on patent expirations.
- Payers: Embrace formulary management emphasizing biosimilars, negotiate better discounts, and promote value-based reimbursement models.
- Healthcare Providers: Educate clinicians on biosimilar safety and efficacy to enhance adoption and influence price sustainability.
- Investors: Monitor patent statuses, regulatory changes, and competitive entries to gauge market volatility and pricing trends.
Key Takeaways
- The market for NDC 00641-6078 operates within a rapidly evolving biosimilar and biologic landscape, with increasing competition driving prices downward.
- Current pricing is influenced heavily by biosimilar entry, reimbursement models, and regional policies aiming for cost containment.
- Price projections suggest a trend of gradual erosion, with significant reductions anticipated by 2025 as patent expirations enable more biosimilar options.
- Strategic focus on early biosimilar development, regulatory agility, and payer engagement offers lucrative opportunities amid this evolution.
- Stakeholders must stay informed on patent timelines, regulatory developments, and payer policies to optimize pricing and market share.
FAQs
1. What is the therapeutic indication for NDC 00641-6078?
It primarily targets [specific condition, e.g., autoimmune diseases, certain cancers], providing biologic therapy or biosimilar options relevant to this patient population.
2. How does patent expiration affect the pricing of this drug?
Patent expiration opens the market for biosimilar competitors, intensifying competition and typically leading to significant price reductions.
3. What are the key factors driving biosimilar adoption?
Cost savings, regulatory approvals, clinician acceptance, and payer incentives are the primary drivers encouraging biosimilar use over originators.
4. What are the main challenges in forecasting biologic drug prices?
Uncertainties include regulatory changes, patent litigations, market competition, reimbursement policies, and supply chain factors.
5. How can manufacturers capitalize on upcoming patent expirations?
Early preparation for biosimilar development, robust regulatory strategies, and proactive payer engagement can maximize market capture and price advantages.
References
- IQVIA Institute for Human Data Science. (2023). The Global Use of Medicines in 2023.
- U.S. Food and Drug Administration. (2022). Biosimilar Product Development & Approval.
- CMS. (2023). Medicare Drug Pricing and Coverage Policies.
- Market Research Future. (2023). Biosimilar Market Analysis and Forecast.
- FDA. (2022). Biosimilar Biological Product Applications: Quality Submissions Guidance.
Note: The specific drug details, price figures, and projections are illustrative and should be corroborated with current market data and regulatory updates.
More… ↓
